North America Facial Injectable Market Size & Outlook
Global Market
Related Markets
North America facial injectable market highlights
- The North America facial injectable market generated a revenue of USD 4,592.9 million in 2025.
- The market is expected to grow at a CAGR of 7.6% from 2026 to 2033.
- In terms of segment, botulinum toxin (botox) was the largest revenue generating product in 2025.
- Calcium Hydroxylapatite (CaHA) is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 4,592.9 million |
| Market revenue in 2033 | USD 8,245.1 million |
| Growth rate | 7.6% (CAGR from 2026 to 2033) |
| Largest segment | Botulinum toxin (botox) |
| Fastest growing segment | Calcium Hydroxylapatite (CaHA) |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Collagen and PMMA Microspheres, Hyaluronic Acid, Calcium Hydroxylapatite (CaHA), PLLA, Botulinum Toxin (Botox) |
| Key market players worldwide | AbbVie Inc, Medytox, Merz Pharma, Revance Therapeutics Inc, Galderma, Sinclair Pharma plc |
Other key industry trends
- In terms of revenue, North America region accounted for 38.9% of the global facial injectable market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,126.5 million by 2033.
North America dominated the market and accounted for the largest revenue share of 38.9% in 2024, driven by an aging population and ongoing regulatory approvals for advanced aesthetic treatments. The FDA’s approval of Juvéderm Voluma XC in March 2024 for treating temple hollowing marks a major milestone, making it the first hyaluronic acid dermal filler approved for this indication, with results lasting up to 13 months. This approval reflects the growing demand for targeted facial rejuvenation solutions as the U.S. population continues to trend older.
Currently, 62 million adults aged 65 and older make up 18% of the U.S. population, a figure projected to reach 84 million (23%) by 2054. Additionally, the number of centenarians is expected to double over the next 30 years, highlighting the increasing consumer base seeking non-surgical anti-aging treatments. As life expectancy rises and minimally invasive aesthetic procedures gain popularity, North America remains a key growth hub for the Facial Injectable Market, with demand for dermal fillers and botulinum toxin treatments surging among both older adults and younger individuals seeking preventative aesthetic enhancements.
No credit card required*
Publish Date: May 06, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Facial Injectable Market Scope
Facial Injectable Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Revance Therapeutics Inc | View profile | 597 | 1222 Demonbreun Street, Suite 2000, Nashville, TN, United States, 37203 | www.revance.com |
| Merz Pharma | View profile | 5001-10000 | Deutsch, Sachsen, Germany, Europe | www.merz.com |
| Sinclair Pharma plc | View profile | 501-1000 | London, England, United Kingdom, Europe | www.sinclairpharma.com/ |
| Medytox | View profile | 501-1000 | Seoul, Seoul-t'ukpyolsi, South Korea, Asia | www.medytox.com/page/company_en?site_id=en |
| Ipsen SA | View profile | 5,325 | 65 Quai Georges Gorse, Billancourt Cedex, Boulogne, France, 92100 | www.ipsen.com |
| Galderma | View profile | 10001+ | Lausanne, Vaud, Switzerland, Europe | www.galderma.com |
North America Facial Injectable Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Facial Injectable Market Outlook will help companies and investors design strategic landscapes.
Botulinum Toxin (Botox) was the largest segment with a revenue share of 49.83% in 2025.
Horizon Databook has segmented the North America facial injectable market based on collagen and pmma microspheres, hyaluronic acid, calcium hydroxylapatite (caha), plla, botulinum toxin (botox) covering the revenue growth of each sub-segment from 2021 to 2033.
North America dominated the market and accounted for the largest revenue share of 38.9% in 2024, driven by an aging population and ongoing regulatory approvals for advanced aesthetic treatments. The FDA’s approval of Juvéderm Voluma XC in March 2024 for treating temple hollowing marks a major milestone, making it the first hyaluronic acid dermal filler approved for this indication, with results lasting up to 13 months. This approval reflects the growing demand for targeted facial rejuvenation solutions as the U.S. population continues to trend older.
Currently, 62 million adults aged 65 and older make up 18% of the U.S. population, a figure projected to reach 84 million (23%) by 2054. Additionally, the number of centenarians is expected to double over the next 30 years, highlighting the increasing consumer base seeking non-surgical anti-aging treatments. As life expectancy rises and minimally invasive aesthetic procedures gain popularity, North America remains a key growth hub for the Facial Injectable Market, with demand for dermal fillers and botulinum toxin treatments surging among both older adults and younger individuals seeking preventative aesthetic enhancements.
- North America Facial Injectable Market Product Outlook (Revenue, USD Million , 2021-2033)
- Collagen and PMMA Microspheres
- Hyaluronic Acid
- Calcium Hydroxylapatite (CaHA)
- PLLA
- PCL
- PN/PDRN
- Botulinum Toxin (Botox)
- Exosome
- North America Facial Injectable Market Applications Outlook (Revenue, USD Million , 2021-2033)
- Wrinkle Correction
- Lip Augmentation
- Facial Contouring
- Scar Treatment
- Volume Loss Restoration
- Others
- North America Facial Injectable Market End Use Outlook (Revenue, USD Million , 2021-2033)
- MedSpas
- Aesthetic Surgery Centers
- Hospitals
- Others
Reasons to subscribe to Facial Injectable Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Facial Injectable Market Outlook databook
- Our clientele includes a mix of Facial Injectable Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Facial Injectable Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Facial Injectable Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
North America Facial Injectable Market, 2021-2033 (US$M)
North America facial injectable market statistics, by product, 2021-2033 (US$M)
